{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:03:25Z","timestamp":1784822605075,"version":"3.55.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100009397","name":"Medizinischen Fakult\u00e4t, Eberhard Karls Universit\u00e4t T\u00fcbingen","doi-asserted-by":"publisher","award":["Clinician Scientist Program grant 439-0-0"],"award-info":[{"award-number":["Clinician Scientist Program grant 439-0-0"]}],"id":[{"id":"10.13039\/501100009397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009397","name":"Medizinischen Fakult\u00e4t, Eberhard Karls Universit\u00e4t T\u00fcbingen","doi-asserted-by":"publisher","award":["Johannes-Dichgans Doctorate Scholarship"],"award-info":[{"award-number":["Johannes-Dichgans Doctorate Scholarship"]}],"id":[{"id":"10.13039\/501100009397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["Clinician Scientist programme \"PRECISE.net\""],"award-info":[{"award-number":["Clinician Scientist programme \"PRECISE.net\""]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["EJP-RD network PROSPAX (No 441409627)"],"award-info":[{"award-number":["EJP-RD network PROSPAX (No 441409627)"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010571","name":"Bundesministerium f\u00fcr Bildung, Wissenschaft, Forschung und Technologie","doi-asserted-by":"publisher","award":["TreatHSP network (grant 01GM2209A)"],"award-info":[{"award-number":["TreatHSP network (grant 01GM2209A)"]}],"id":[{"id":"10.13039\/501100010571","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40120-026-00950-y","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T16:18:17Z","timestamp":1781540297000},"page":"1993-2009","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Digital Motor Outcomes Capture Upper Limb and Mild Stage Impairment in Hereditary Spastic Paraplegia"],"prefix":"10.1007","volume":"15","author":[{"given":"Malin","family":"Schulze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Hermle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Barallon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried","family":"Ilg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Sch\u00fcle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Reilmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthis","family":"Synofzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8165-5898","authenticated-orcid":false,"given":"Andreas","family":"Trasch\u00fctz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"950_CR1","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/B978-0-444-64076-5.00041-7","volume":"148","author":"C Blackstone","year":"2018","unstructured":"Blackstone C. Hereditary spastic paraplegia. Handb Clin Neurol. 2018;148:633\u201352.","journal-title":"Handb Clin Neurol"},{"issue":"12","key":"950_CR2","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/S1474-4422(19)30235-2","volume":"18","author":"S Shribman","year":"2019","unstructured":"Shribman S, Reid E, Crosby AH, Houlden H, Warner TT. Hereditary spastic paraplegia: from diagnosis to emerging therapeutic approaches. Lancet Neurol. 2019;18(12):1136\u201346.","journal-title":"Lancet Neurol"},{"issue":"7","key":"950_CR3","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1038\/s41591-024-03078-4","volume":"30","author":"JJ Dowling","year":"2024","unstructured":"Dowling JJ, Pirovolakis T, Devakandan K, Stosic A, Pidsadny M, Nigro E, et al. AAV gene therapy for hereditary spastic paraplegia type 50: a phase 1 trial in a single patient. Nat Med. 2024;30(7):1882\u20137.","journal-title":"Nat Med"},{"key":"950_CR4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/B978-0-323-98817-9.00022-3","volume":"196","author":"JK Fink","year":"2023","unstructured":"Fink JK. The hereditary spastic paraplegias. Handb Clin Neurol. 2023;196:59\u201388.","journal-title":"Handb Clin Neurol"},{"issue":"9","key":"950_CR5","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.3390\/genes14091756","volume":"14","author":"S-F Siow","year":"2023","unstructured":"Siow S-F, Yeow D, Rudaks LI, Jia F, Wali G, Sue CM, et al. Outcome measures and biomarkers for clinical trials in Hereditary Spastic Paraplegia: a scoping review. Genes Basel. 2023;14(9):1756.","journal-title":"Genes Basel"},{"issue":"4","key":"950_CR6","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/ana.24611","volume":"79","author":"R Sch\u00fcle","year":"2016","unstructured":"Sch\u00fcle R, Wiethoff S, Martus P, Karle KN, Otto S, Klebe S, et al. Hereditary spastic paraplegia: clinicogenetic lessons from 608 patients. Ann Neurol. 2016;79(4):646\u201358.","journal-title":"Ann Neurol"},{"key":"950_CR7","doi-asserted-by":"publisher","first-page":"1098454","DOI":"10.3389\/fneur.2023.1098454","volume":"14","author":"A Videnovic","year":"2023","unstructured":"Videnovic A, Pfeiffer HC, Tylki-Szyma\u0144ska A, Berry-Kravis E, Ezg\u00fc F, Ganju J, et al. Study design challenges and strategies in clinical trials for rare diseases: lessons learned from pantothenate kinase-associated neurodegeneration. Front Neurol. 2023;14:1098454.","journal-title":"Front Neurol"},{"issue":"2","key":"950_CR8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/mds.30056","volume":"40","author":"P R\u00e1bano-Su\u00e1rez","year":"2025","unstructured":"R\u00e1bano-Su\u00e1rez P, Del Campo N, Benatru I, Moreau C, Desjardins C, S\u00e1nchez-Ferro \u00c1, et al. Digital outcomes as biomarkers of disease progression in early parkinson\u2019s disease: a systematic review. Mov Disord. 2025;40(2):184\u2013203.","journal-title":"Mov Disord"},{"issue":"3","key":"950_CR9","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S1474-4422(23)00454-4","volume":"23","author":"R Reilmann","year":"2024","unstructured":"Reilmann R, Anderson KE, Feigin A, Tabrizi SJ, Leavitt BR, Stout JC, et al. Safety and efficacy of laquinimod for Huntington\u2019s disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Neurol. 2024;23(3):243\u201355.","journal-title":"Lancet Neurol"},{"issue":"2","key":"950_CR10","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S1474-4422(18)30391-0","volume":"18","author":"R Reilmann","year":"2019","unstructured":"Reilmann R, McGarry A, Grachev ID, Savola J-M, Borowsky B, Eyal E, et al. Safety and efficacy of pridopidine in patients with Huntington\u2019s disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. Lancet Neurol. 2019;18(2):165\u201376.","journal-title":"Lancet Neurol"},{"issue":"11","key":"950_CR11","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1002\/mds.29206","volume":"37","author":"W Ilg","year":"2022","unstructured":"Ilg W, Muller B, Faber J, van Gaalen J, Hengel H, Vogt IR, et al. Digital gait biomarkers allow to capture 1-year longitudinal change in spinocerebellar ataxia type 3. Mov Disord. 2022;37(11):2295\u2013301.","journal-title":"Mov Disord"},{"issue":"12","key":"950_CR12","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1002\/mds.29199","volume":"37","author":"C Lassmann","year":"2022","unstructured":"Lassmann C, Ilg W, Schneider M, Volker M, Haeufle DFB, Schule R, et al. Specific gait changes in prodromal hereditary spastic paraplegia type 4: preSPG4 study. Mov Disord. 2022;37(12):2417\u201326.","journal-title":"Mov Disord"},{"issue":"10","key":"950_CR13","doi-asserted-by":"publisher","first-page":"e1079","DOI":"10.1212\/WNL.0000000000200819","volume":"99","author":"M Regensburger","year":"2022","unstructured":"Regensburger M, Spatz IT, Ollenschl\u00e4ger M, Martindale CF, Lindeburg P, Kohl Z, et al. Inertial gait sensors to measure mobility and functioning in hereditary spastic paraplegia: a cross-sectional multicenter clinical study. Neurology. 2022;99(10):e1079\u201389.","journal-title":"Neurology"},{"issue":"1","key":"950_CR14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/s13023-023-02854-8","volume":"18","author":"M Ollenschl\u00e4ger","year":"2023","unstructured":"Ollenschl\u00e4ger M, H\u00f6fner P, Ullrich M, Kluge F, Greinwalder T, Loris E, et al. Automated assessment of foot elevation in adults with hereditary spastic paraplegia using inertial measurements and machine learning. Orphanet J Rare Dis. 2023;18(1):249.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"950_CR15","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1007\/s12311-019-01073-x","volume":"18","author":"C Hohenfeld","year":"2019","unstructured":"Hohenfeld C, Dogan I, Schubert R, Didszun C, Sch\u00f6ls L, Synofzik M, et al. Application of quantitative motor assessments in Friedreich ataxia and evaluation of their relation to clinical measures. Cerebellum. 2019;18(5):896\u2013909.","journal-title":"Cerebellum"},{"key":"950_CR16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/B978-0-12-801893-4.00018-3","volume":"144","author":"R Reilmann","year":"2017","unstructured":"Reilmann R, Schubert R. Motor outcome measures in Huntington disease clinical trials. Handb Clin Neurol. 2017;144:209\u201325.","journal-title":"Handb Clin Neurol"},{"issue":"6","key":"950_CR17","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.3233\/JPD-223264","volume":"12","author":"KB Wilkins","year":"2022","unstructured":"Wilkins KB, Petrucci MN, Kehnemouyi Y, Velisar A, Han K, Orthlieb G, et al. Quantitative digitography measures motor symptoms and disease progression in Parkinson\u2019s disease. J Parkinsons Dis. 2022;12(6):1979\u201390.","journal-title":"J Parkinsons Dis"},{"issue":"3","key":"950_CR18","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/brain\/awg069","volume":"126","author":"J Duque","year":"2003","unstructured":"Duque J, Thonnard JL, Vandermeeren Y, S\u00e9bire G, Cosnard G, Olivier E. Correlation between impaired dexterity and corticospinal tract dysgenesis in congenital hemiplegia. Brain. 2003;126(3):732\u201347.","journal-title":"Brain"},{"issue":"3","key":"950_CR19","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1123\/mcj.7.3.304","volume":"7","author":"DA Nowak","year":"2003","unstructured":"Nowak DA, Hermsd\u00f6rfer J, Topka H. When motor execution is selectively impaired: control of manipulative finger forces in amyotrophic lateral sclerosis. Mot Control. 2003;7(3):304\u201320.","journal-title":"Mot Control"},{"issue":"4","key":"950_CR20","doi-asserted-by":"publisher","first-page":"e0153283","DOI":"10.1371\/journal.pone.0153283","volume":"11","author":"A Martinuzzi","year":"2016","unstructured":"Martinuzzi A, Montanaro D, Vavla M, Paparella G, Bonanni P, Musumeci O, et al. Clinical and paraclinical indicators of motor system impairment in hereditary spastic paraplegia: a pilot study. PLoS ONE. 2016;11(4):e0153283.","journal-title":"PLoS ONE"},{"issue":"4","key":"950_CR21","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamaneurol.2013.1956","volume":"70","author":"JL Loureiro","year":"2013","unstructured":"Loureiro JL, Brandao E, Ruano L, Brandao AF, Lopes AM, Thieleke-Matos C, et al. Autosomal dominant spastic paraplegias: a review of 89 families resulting from a portuguese survey. JAMA Neurol. 2013;70(4):481\u20137.","journal-title":"JAMA Neurol"},{"issue":"5","key":"950_CR22","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1093\/brain\/awac391","volume":"146","author":"A Saffari","year":"2023","unstructured":"Saffari A, Kellner M, Jordan C, Rosengarten H, Mo A, Zhang B, et al. The clinical and molecular spectrum of ZFYVE26-associated hereditary spastic paraplegia: SPG15. Brain. 2023;146(5):2003\u201315.","journal-title":"Brain"},{"issue":"S6","key":"950_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/(SICI)1097-4598(1997)6+<1::AID-MUS2>3.0.CO;2-D","volume":"20","author":"NH Mayer","year":"1997","unstructured":"Mayer NH. Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion. Muscle Nerve. 1997;20(S6):1\u201314.","journal-title":"Muscle Nerve"},{"key":"950_CR24","doi-asserted-by":"crossref","unstructured":"Fink JK, editor Progressive spastic paraparesis: hereditary spastic paraplegia and its relation to primary and amyotrophic lateral sclerosis. Seminars in neurology; 2001: Copyright\u00a9 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New\u00a0\u2026.","DOI":"10.1055\/s-2001-15265"},{"issue":"3","key":"950_CR25","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1212\/01.wnl.0000228242.53336.90","volume":"67","author":"R Sch\u00fcle","year":"2006","unstructured":"Sch\u00fcle R, Holland-Letz T, Klimpe S, Kassubek J, Klopstock T, Mall V, et al. The spastic paraplegia rating scale (SPRS) a reliable and valid measure of disease severity. Neurology. 2006;67(3):430\u20134.","journal-title":"Neurology"},{"issue":"2","key":"950_CR26","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1080\/1357650X.2013.783045","volume":"19","author":"JF Veale","year":"2014","unstructured":"Veale JF. Edinburgh handedness inventory\u2013short form: a revised version based on confirmatory factor analysis. Laterality. 2014;19(2):164\u201377.","journal-title":"Laterality"},{"issue":"7","key":"950_CR27","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1212\/01.WNL.0000156802.15466.79","volume":"64","author":"S Subramony","year":"2005","unstructured":"Subramony S, May W, Lynch D, Gomez C, Fischbeck K, Hallett M, et al. Measuring Friedreich ataxia: interrater reliability of a neurologic rating scale. Neurology. 2005;64(7):1261\u20132.","journal-title":"Neurology"},{"issue":"4","key":"950_CR28","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s00415-009-5352-7","volume":"257","author":"LA Corben","year":"2010","unstructured":"Corben LA, Tai G, Wilson C, Collins V, Churchyard AJ, Delatycki MB. A comparison of three measures of upper limb function in Friedreich ataxia. J Neurol. 2010;257(4):518\u201323.","journal-title":"J Neurol"},{"issue":"1","key":"950_CR29","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1177\/153944928500500102","volume":"5","author":"V Mathiowetz","year":"1985","unstructured":"Mathiowetz V, Weber K, Kashman N, Volland G. Adult norms for the nine hole peg test of finger dexterity. Occup Ther J Res. 1985;5(1):24\u201338.","journal-title":"Occup Ther J Res"},{"issue":"5","key":"950_CR30","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/acn3.52024","volume":"11","author":"D Hermle","year":"2024","unstructured":"Hermle D, Schubert R, Barallon P, Ilg W, Sch\u00fcle R, Reilmann R, et al. Multifeature quantitative motor assessment of upper limb ataxia including drawing and reaching. Ann Clin Transl Neurol. 2024;11(5):1097\u2013109.","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"950_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41746-020-0286-7","volume":"3","author":"CM Kanzler","year":"2020","unstructured":"Kanzler CM, Rinderknecht MD, Schwarz A, Lamers I, Gagnon C, Held JP, et al. A data-driven framework for selecting and validating digital health metrics: use-case in neurological sensorimotor impairments. NPJ Digit Med. 2020;3(1):1\u201317.","journal-title":"NPJ Digit Med"},{"issue":"12","key":"950_CR32","doi-asserted-by":"publisher","first-page":"e209887","DOI":"10.1212\/WNL.0000000000209887","volume":"103","author":"L Beichert","year":"2024","unstructured":"Beichert L, Seemann J, Kessler C, Trasch\u00fctz A, M\u00fcller D, Dillmann-Jehn K, et al. Patient-relevant digital-motor outcomes for clinical trials in hereditary spastic paraplegia type 7: a multicenter PROSPAX study. Neurology. 2024;103(12):e209887.","journal-title":"Neurology"},{"issue":"2","key":"950_CR33","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.gaitpost.2011.09.018","volume":"35","author":"J Marsden","year":"2012","unstructured":"Marsden J, Ramdharry G, Stevenson V, Thompson A. Muscle paresis and passive stiffness: key determinants in limiting function in hereditary and sporadic spastic paraparesis. Gait Posture. 2012;35(2):266\u201371.","journal-title":"Gait Posture"},{"issue":"4","key":"950_CR34","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.gaitpost.2011.01.009","volume":"33","author":"SI Wolf","year":"2011","unstructured":"Wolf SI, Braatz F, Metaxiotis D, Armbrust P, Dreher T, D\u00f6derlein L, et al. Gait analysis may help to distinguish hereditary spastic paraplegia from cerebral palsy. Gait Posture. 2011;33(4):556\u201361.","journal-title":"Gait Posture"},{"issue":"2","key":"950_CR35","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.gaitpost.2012.12.006","volume":"38","author":"M de Niet","year":"2013","unstructured":"de Niet M, Weerdesteyn V, de Bot ST, van de Warrenburg BP, Geurts AC. Does calf muscle spasticity contribute to postural imbalance? A study in persons with pure hereditary spastic paraparesis. Gait Posture. 2013;38(2):304\u20139.","journal-title":"Gait Posture"},{"issue":"3","key":"950_CR36","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/j.1525-1403.2012.00494.x","volume":"16","author":"J Marsden","year":"2013","unstructured":"Marsden J, Stevenson V, McFadden C, Swain I, Taylor P. The effects of functional electrical stimulation on walking in hereditary and spontaneous spastic paraparesis. Neuromodulation. 2013;16(3):256\u201360.","journal-title":"Neuromodulation"},{"issue":"4","key":"950_CR37","first-page":"419","volume":"16","author":"BC Heiderscheit","year":"2000","unstructured":"Heiderscheit BC. Movement variability as a clinical measure for locomotion. J Appl Biomech. 2000;16(4):419\u201327.","journal-title":"J Appl Biomech"},{"issue":"6","key":"950_CR38","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3390\/medicina46060054","volume":"46","author":"ML Latash","year":"2010","unstructured":"Latash ML, Levin MF, Scholz JP, Sch\u00f6ner G. Motor control theories and their applications. Medicina (Kaunas). 2010;46(6):382.","journal-title":"Medicina (Kaunas)"},{"key":"950_CR39","doi-asserted-by":"publisher","first-page":"667","DOI":"10.3389\/fnhum.2015.00667","volume":"9","author":"S Kubota","year":"2015","unstructured":"Kubota S, Hirano M, Koizume Y, Tanabe S, Funase K. Changes in the spinal neural circuits are dependent on the movement speed of the visuomotor task. Front Hum Neurosci. 2015;9:667.","journal-title":"Front Hum Neurosci"},{"issue":"10","key":"950_CR40","doi-asserted-by":"publisher","first-page":"e0164623","DOI":"10.1371\/journal.pone.0164623","volume":"11","author":"M Serrao","year":"2016","unstructured":"Serrao M, Rinaldi M, Ranavolo A, Lacquaniti F, Martino G, Leonardi L, et al. Gait patterns in patients with hereditary spastic paraparesis. PLoS ONE. 2016;11(10):e0164623.","journal-title":"PLoS ONE"},{"issue":"5","key":"950_CR41","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/mus.20285","volume":"31","author":"JM Gracies","year":"2005","unstructured":"Gracies JM. Pathophysiology of spastic paresis. II: emergence of muscle overactivity. Muscle Nerve. 2005;31(5):552\u201371.","journal-title":"Muscle Nerve"},{"key":"950_CR42","unstructured":"FDA. Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments Into Endpoints for Regulatory Decision-Making: U.S. Food and Drug Administration; 2023 [Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-incorporating-clinical-outcome-assessments-endpoints-regulatory."},{"key":"950_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/mds.70012","author":"D Hermle","year":"2025","unstructured":"Hermle D, Schubert R, Barallon P, Ilg W, Schule R, Reilmann R, et al. Digital outcomes of upper limb ataxia capture meaningful longitudinal change and treatment response. Mov Disord. 2025. https:\/\/doi.org\/10.1002\/mds.70012.","journal-title":"Mov Disord"},{"issue":"3","key":"950_CR44","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/mds.26944","volume":"32","author":"M Synofzik","year":"2017","unstructured":"Synofzik M, Sch\u00fcle R. Overcoming the divide between ataxias and spastic paraplegias: shared phenotypes, genes, and pathways. Mov Disord. 2017;32(3):332\u201345.","journal-title":"Mov Disord"},{"key":"950_CR45","unstructured":"PROSPAX: an integrated multimodal progression chart in spastic ataxias [Available from: https:\/\/www.prospax.net\/."},{"key":"950_CR46","unstructured":"FDA. Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments: U.S. Food and Drug Administration; 2022 [Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-selecting-developing-or-modifying-fit-purpose-clinical-outcome."},{"key":"950_CR47","doi-asserted-by":"publisher","DOI":"10.1007\/s12311-023-01565-x","author":"M Tremblay","year":"2023","unstructured":"Tremblay M, Brais B, Asselin V, Buffet M, Girard A, Girard D, et al. The development of a new patient-reported outcome measure in recessive ataxias: the person-reported ataxia impact scale. Cerebellum. 2023. https:\/\/doi.org\/10.1007\/s12311-023-01565-x.","journal-title":"Cerebellum"},{"issue":"10","key":"950_CR48","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1002\/mds.28670","volume":"36","author":"JD Schmahmann","year":"2021","unstructured":"Schmahmann JD, Pierce S, MacMore J, L\u2019Italien GJ. Development and validation of a patient-reported outcome measure of ataxia. Mov Disord. 2021;36(10):2367\u201377.","journal-title":"Mov Disord"},{"key":"950_CR49","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-225122","author":"JR Mammen","year":"2023","unstructured":"Mammen JR, Speck RM, Stebbins GM, M\u00fcller ML, Yang PT, Campbell M, et al. Mapping relevance of digital measures to meaningful symptoms and impacts in early Parkinson\u2019s disease. J Parkinson\u2019s Dis. 2023. https:\/\/doi.org\/10.3233\/JPD-225122.","journal-title":"J Parkinson\u2019s Dis"},{"issue":"7","key":"950_CR50","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S1474-4422(13)70088-7","volume":"12","author":"SJ Tabrizi","year":"2013","unstructured":"Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington\u2019s disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol. 2013;12(7):637\u201349.","journal-title":"Lancet Neurol"},{"issue":"9","key":"950_CR51","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1474-4422(09)70170-X","volume":"8","author":"SJ Tabrizi","year":"2009","unstructured":"Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, et al. Biological and clinical manifestations of Huntington\u2019s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 2009;8(9):791\u2013801.","journal-title":"Lancet Neurol"},{"issue":"3","key":"950_CR52","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s12311-025-01820-3","volume":"24","author":"IH Willemse","year":"2025","unstructured":"Willemse IH, Mellone S, Tacconi C, Ilg W, Sch\u00fcle R, Synofzik M, et al. Smartphone application for spastic ataxias cross-sectional validation of a newly developed smartphone app for remote monitoring in spastic ataxias. Cerebellum. 2025;24(3):71.","journal-title":"Cerebellum"},{"key":"950_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03920-3","author":"R Reilmann","year":"2025","unstructured":"Reilmann R, Feigin A, Rosser AE, Kostyk SK, Saft C, Cohen Y, et al. Pridopidine in early-stage manifest Huntington\u2019s disease: a phase 3 trial. Nat Med. 2025. https:\/\/doi.org\/10.1038\/s41591-025-03920-3.","journal-title":"Nat Med"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00950-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00950-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00950-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:11:27Z","timestamp":1784819487000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00950-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["950"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00950-y","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Robin Schubert and Pascal Barallon are employees, and Ralf Reilmann is director, of both the George-Huntington-Institute and QuantiMedis manufacturing Q-Motor devices and software and providing Q-Motor services for research projects and sponsors. Matthis Synofzik has received consultancy honoraria from Ionis, UCB, Prevail, Orphazyme, Servier, Reata, GenOrph, AviadoBio, Biohaven, Zevra, and Lilly, all unrelated to the present manuscript. Dominik Hermle, Winfried Ilg, Rebecca Sch\u00fcle, Andreas Trasch\u00fctz, and Malin Schulze have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the Helsinki Declaration of 1964 and approved by the Institutional Review Board of the Medical Faculty of the University of T\u00fcbingen (423\/2019BO1), and all subjects provided written informed consent.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}